Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma

MLA

Fabienne Hollinger, et al. “Phase II Study of 131I-MIBG with Vincristine and 5 Days of Irinotecan for Patients with Relapsed or Refractory Neuroblastoma.” Journal of Clinical Oncology, vol. 32, May 2014, p. 10033. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b55e4b4dab6a455b7ccbd683143fc598&authtype=sso&custid=ns315887.

APA

Fabienne Hollinger, M. Shelly Allen, Yael P. Mosse, Katherine K. Matthay, Melissa A. Bent, Steven G. DuBois, Joan F. Hilton, Randall A. Hawkins, & Jesse Courtier. (2014). Phase II study of 131I-MIBG with vincristine and 5 days of irinotecan for patients with relapsed or refractory neuroblastoma. Journal of Clinical Oncology, 32, 10033.

Chicago

Fabienne Hollinger, M. Shelly Allen, Yael P. Mosse, Katherine K. Matthay, Melissa A. Bent, Steven G. DuBois, Joan F. Hilton, Randall A. Hawkins, and Jesse Courtier. 2014. “Phase II Study of 131I-MIBG with Vincristine and 5 Days of Irinotecan for Patients with Relapsed or Refractory Neuroblastoma.” Journal of Clinical Oncology 32 (May): 10033. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........b55e4b4dab6a455b7ccbd683143fc598&authtype=sso&custid=ns315887.